6月11日，晶泰控股盘中下跌5.02%，报6.62港元/股，成交额1.69亿港元。
消息面上，公司近日接连发布超4亿美元AI药物发现战略合作及1亿美元股份回购计划，但市场反应冷淡。此前合作公告仅带动股价短暂高开4%即回落，回购计划亦未能扭转颓势。尽管公司营收同比增长超200%并首次实现年度盈利，但动态市盈率仍高达212倍，叠加生命科学板块整体承压，高估值回归压力持续主导股价走势。行业内药明合联跌5.47%，英矽智能跌6.58%，板块情绪偏弱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.